These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 38688353

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of urinary tract infections in the era of antimicrobial resistance and new antimicrobial agents.
    Bader MS, Loeb M, Leto D, Brooks AA.
    Postgrad Med; 2020 Apr; 132(3):234-250. PubMed ID: 31608743
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
    Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
    [Abstract] [Full Text] [Related]

  • 9. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS, Loeb M, Brooks AA.
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [Abstract] [Full Text] [Related]

  • 10. Clinical data from studies involving novel antibiotics to treat multidrug-resistant Gram-negative bacterial infections.
    Kanj SS, Bassetti M, Kiratisin P, Rodrigues C, Villegas MV, Yu Y, van Duin D.
    Int J Antimicrob Agents; 2022 Sep; 60(3):106633. PubMed ID: 35787918
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain.
    Hernández-García M, García-Castillo M, Ruiz-Garbajosa P, Bou G, Siller-Ruiz M, Pitart C, Gracia-Ahufinger I, Mulet X, Pascual Á, Tormo N, Cantón R.
    Antimicrob Agents Chemother; 2022 Mar 15; 66(3):e0216121. PubMed ID: 35007130
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The β-Lactams Strike Back: Ceftazidime-Avibactam.
    Zasowski EJ, Rybak JM, Rybak MJ.
    Pharmacotherapy; 2015 Aug 15; 35(8):755-70. PubMed ID: 26289307
    [Abstract] [Full Text] [Related]

  • 19. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA.
    Drugs; 2018 Jan 15; 78(1):65-98. PubMed ID: 29230684
    [Abstract] [Full Text] [Related]

  • 20. Cefepime/tazobactam compared with other tazobactam combinations against problem Gram-negative bacteria.
    Mushtaq S, Garello P, Vickers A, Woodford N, Livermore DM.
    Int J Antimicrob Agents; 2021 May 15; 57(5):106318. PubMed ID: 33716176
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.